APA (7th ed.) Citation

Anker, S. D., Friede, T., Butler, J., Talha, K. M., Placzek, M., Diek, M., . . . Macdougall, I. C. (2025). Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR‐HF2‐DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials. European Journal of Heart Failure, 27(8), 1436. https://doi.org/10.1002/ejhf.3658

Chicago Style (17th ed.) Citation

Anker, Stefan D., et al. "Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure (FAIR‐HF2‐DZHK05) Trial: Baseline Characteristics and Comparison to Other Relevant Clinical Trials." European Journal of Heart Failure 27, no. 8 (2025): 1436. https://doi.org/10.1002/ejhf.3658.

MLA (9th ed.) Citation

Anker, Stefan D., et al. "Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure (FAIR‐HF2‐DZHK05) Trial: Baseline Characteristics and Comparison to Other Relevant Clinical Trials." European Journal of Heart Failure, vol. 27, no. 8, 2025, p. 1436, https://doi.org/10.1002/ejhf.3658.